宿主调节与牙周病治疗
本文综述了近年来应用于人体的宿主调节药物及其靶向的关键免疫通路,涵盖合成与生物类改善病情抗风湿药、益生菌、n-3脂肪酸、他汀类等。文章指出部分药物在牙周非手术治疗后改善临床参数,益生菌与n-3脂肪酸联合牙周治疗有抗炎获益,而他汀或双膦酸盐局部辅助治疗尚缺乏充分科学支持。
要点
- 抗CD20与抗IL-6受体单抗可减轻牙周炎症、改善牙周状况。
- 益生菌经抑制NF-κB通路减少促炎因子并促进T调节细胞积聚。
- 他汀或双膦酸盐局部辅助牙周治疗目前缺乏充分科学支持。
核心结论
- 新兴证据提示SPMs与补体抑制剂等新药候选物未来可能为牙周病辅助治疗提供策略。
研究设计与样本
- 本文为对最新应用于人类的宿主调节药物及其靶向免疫通路的批判性综述。
主要发现
- 合成改善病情抗风湿药在类风湿关节炎患者牙周非手术治疗后改善牙周临床参数。
- 抗CD20(利妥昔单抗)与抗IL-6受体(托珠单抗)治疗降低牙周炎症并改善牙周状况。
- TNF-α抑制剂在牙周炎患者中的研究结果不一致。
- 益生菌提供抗炎临床获益,n-3脂肪酸等营养补充剂联合牙周治疗亦有获益。
- 益生菌通过抑制NF-κB通路减少促炎细胞因子/趋化因子产生并促进T调节细胞积聚。
关键数值与推荐
- 他汀类与阿司匹林通过上调SPMs产生表现抗炎与保骨作用。
- 目前缺乏充分科学支持他汀或双膦酸盐局部递送作为牙周治疗辅助手段。
临床怎么用
- 牙周治疗时可关注宿主调节药物作为辅助策略的潜在价值,但局部他汀或双膦酸盐辅助尚无充分证据。
局限性
- TNF-α抑制剂相关研究结果不一致,部分药物证据仍有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Periodontitis is the sixth-most prevalent disease in the world and the first cause for tooth loss in adults. With focus shifted to the inflammatory/immune response in the pathogenesis of periodontitis, there is a critical need to evaluate host modulatory agents. Synthetic and biological disease-modifying antirheumatic drugs are a cornerstone for the treatment of inflammatory diseases. Recent prospective cohort studies showed that synthetic disease-modifying antirheumatic drugs improved periodontal clinical parameters following nonsurgical periodontal treatment in patients with rheumatoid arthritis. Treatment with recombinant humanized monoclonal antibodies against CD20 (rituximab) and IL-6 receptor (tocilizumab), the latter also in clinical trials for the treatment of COVID-19 pneumonia, resulted in decreased periodontal inflammation and improved periodontal status. Studies on the effect of TNF-α inhibitors in patients with periodontitis yielded inconsistent results. Recent data suggest that probiotics provide anti-inflammatory clinical benefit, as do nutritional supplements, such as n-3 fatty acids, when combined with periodontal therapy. Probiotics reduce the production of proinflammatory cytokines/chemokines by suppressing NF-κB pathways and promote the accumulation of T regulatory cells. Statins, like aspirin, have been shown to exhibit anti-inflammatory and bone-preserving actions by upregulating production of Specialized Proresolving Mediators (SPMs). Currently, there is insufficient scientific support for the topical delivery of statins or bisphosphonates as adjuncts to periodontal therapy. Here, we present a critical review of the most recent host modulatory agents applied in humans and the key immune pathways that they target. Emerging evidence from novel drug candidates, including SPMs and complement inhibitors as previously studied in animal models and currently in human clinical trials, suggests future availability of adjunctive therapeutic strategies for the management of periodontitis.
引用
- Balta MG, Papathanasiou E, Blix IJ, et al. Host Modulation and Treatment of Periodontal Disease. J Dent Res. 2021. PMID: 33655803. doi:10.1177/0022034521995157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。